$CTSO
Cytosorbents Corp

2021 Q1 Form 10-Q Financial Statement

#000110465921060974 Filed on May 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $10.60M $8.707M
YoY Change 21.72% 67.72%
Cost Of Revenue $2.751M $2.385M
YoY Change 15.37% 37.17%
Gross Profit $7.847M $6.322M
YoY Change 24.12% 83.1%
Gross Profit Margin 74.04% 72.61%
Selling, General & Admin $7.710M $6.317M
YoY Change 22.05% 32.76%
% of Gross Profit 98.25% 99.91%
Research & Development $2.282M $1.965M
YoY Change 16.12% -18.74%
% of Gross Profit 29.08% 31.08%
Depreciation & Amortization $160.0K $180.0K
YoY Change -11.11% 28.57%
% of Gross Profit 2.04% 2.85%
Operating Expenses $10.70M $8.801M
YoY Change 21.57% 13.74%
Operating Profit -$2.852M -$2.479M
YoY Change 15.07% -42.16%
Interest Expense -$10.12K -$305.5K
YoY Change -96.69% 48.91%
% of Operating Profit
Other Income/Expense, Net -$1.316M -$974.0K
YoY Change 35.07% 62.71%
Pretax Income -$4.168M -$3.453M
YoY Change 20.71% -29.3%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.168M -$3.453M
YoY Change 20.71% -29.3%
Net Earnings / Revenue -39.32% -39.65%
Basic Earnings Per Share -$0.10 -$0.10
Diluted Earnings Per Share -$0.10 -$0.10
COMMON SHARES
Basic Shares Outstanding 43.24M
Diluted Shares Outstanding 43.32M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.50M $26.40M
YoY Change 159.47% 34.69%
Cash & Equivalents $68.47M $26.39M
Short-Term Investments
Other Short-Term Assets $3.000M $3.800M
YoY Change -21.05% 442.86%
Inventory $3.108M $2.000M
Prepaid Expenses
Receivables $5.019M $5.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $79.63M $37.50M
YoY Change 112.36% 51.04%
LONG-TERM ASSETS
Property, Plant & Equipment $2.405M $3.000M
YoY Change -19.83% 58.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.515M $3.700M
YoY Change 22.04% 27.11%
Total Long-Term Assets $7.844M $6.700M
YoY Change 17.08% 8.65%
TOTAL ASSETS
Total Short-Term Assets $79.63M $37.50M
Total Long-Term Assets $7.844M $6.700M
Total Assets $87.48M $44.20M
YoY Change 97.92% 42.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.678M $1.800M
YoY Change -6.8% -2.21%
Accrued Expenses $8.100M $5.500M
YoY Change 47.27% 71.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.200M
YoY Change 152.0%
Total Short-Term Liabilities $9.759M $11.50M
YoY Change -15.14% 71.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $10.90M
YoY Change -100.0% 31.35%
Other Long-Term Liabilities $500.0K $500.0K
YoY Change 0.0% -50.0%
Total Long-Term Liabilities $500.0K $11.40M
YoY Change -95.61% 37.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.759M $11.50M
Total Long-Term Liabilities $500.0K $11.40M
Total Liabilities $10.22M $22.90M
YoY Change -55.37% 43.31%
SHAREHOLDERS EQUITY
Retained Earnings -$200.8M
YoY Change
Common Stock $43.27K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.26M $21.31M
YoY Change
Total Liabilities & Shareholders Equity $87.48M $44.20M
YoY Change 97.92% 42.6%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$4.168M -$3.453M
YoY Change 20.71% -29.3%
Depreciation, Depletion And Amortization $160.0K $180.0K
YoY Change -11.11% 28.57%
Cash From Operating Activities -$2.344M -$3.209M
YoY Change -26.96% -24.26%
INVESTING ACTIVITIES
Capital Expenditures $428.6K $235.6K
YoY Change 81.97% -19.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$606.3K -$508.6K
YoY Change 19.23% 7.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $27.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 76.55K 17.88M
YoY Change -99.57% 792.05%
NET CHANGE
Cash From Operating Activities -2.344M -3.209M
Cash From Investing Activities -606.3K -508.6K
Cash From Financing Activities 76.55K 17.88M
Net Change In Cash -2.953M 14.16M
YoY Change -120.86% -622.92%
FREE CASH FLOW
Cash From Operating Activities -$2.344M -$3.209M
Capital Expenditures $428.6K $235.6K
Free Cash Flow -$2.773M -$3.445M
YoY Change -19.51% -23.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q3 ctso Aggregate Registered Amount For Offerings
AggregateRegisteredAmountForOfferings
150000000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4301869
CY2021Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P35M
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001175151
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43272372
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43221999
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36792
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
CYTOSORBENTS CORPORATION
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0373793
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7 Deer Park Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite K
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Monmouth Junction
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08852
CY2021Q1 dei City Area Code
CityAreaCode
732
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
329-8885
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 dei Trading Symbol
TradingSymbol
CTSO
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43319297
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68468285
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71421601
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
65026
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
46851
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5018506
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5159275
CY2021Q1 us-gaap Inventory Net
InventoryNet
3108201
CY2020Q4 us-gaap Inventory Net
InventoryNet
2673799
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3039722
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3198460
CY2021Q1 us-gaap Assets Current
AssetsCurrent
79634714
CY2020Q4 us-gaap Assets Current
AssetsCurrent
82453135
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2404958
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2119927
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
923960
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1029123
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4515420
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4348286
CY2021Q1 us-gaap Assets
Assets
87479052
CY2020Q4 us-gaap Assets
Assets
89950471
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1677565
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1835082
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
462896
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
447485
CY2021Q1 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7618726
CY2020Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7870687
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9759187
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10153254
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
461064
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581638
CY2021Q1 us-gaap Liabilities
Liabilities
10220251
CY2020Q4 us-gaap Liabilities
Liabilities
10734892
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43272372
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43221999
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
43272
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43222
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
278586339
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
277533082
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-576342
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1734078
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200794468
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196626647
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
77258801
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79215579
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87479052
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89950471
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10598847
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8707310
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2751444
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2384842
CY2021Q1 us-gaap Gross Profit
GrossProfit
7847403
CY2020Q1 us-gaap Gross Profit
GrossProfit
6322468
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2282052
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1965286
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
707839
CY2020Q1 us-gaap Professional Fees
ProfessionalFees
519002
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7709703
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6316934
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
10699594
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
8801222
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2852191
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2478754
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-10124
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-305537
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1305506
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-668488
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1315630
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-974025
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4167821
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3452779
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4167821
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3452779
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43242791
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33981262
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4167821
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3452779
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1157736
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
609828
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3010085
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2842951
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79215579
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
667193
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1157736
CY2021Q1 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
76553
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
309561
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4167821
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
77258801
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3418042
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
729429
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
609828
CY2020Q1 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
138430
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
328939
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19541621
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3452779
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
21313510
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4167821
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3452779
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
442273
CY2020Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
477732
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
156322
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
181368
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
35868
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
19720
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7862
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
667193
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
729429
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1305506
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-668488
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28046
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1023329
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
492815
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-134270
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-144489
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-87107
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
23501
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-367557
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1055356
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2344237
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3209340
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
428638
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235551
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
177703
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
273011
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-606341
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-508562
CY2021Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
0
CY2020Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
17743226
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76553
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
138430
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76553
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17881656
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-79291
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7151
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2953316
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14156603
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71421601
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12232418
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68468285
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26389021
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
318879
CY2021Q1 us-gaap Stock Issued1
StockIssued1
309561
CY2020Q1 us-gaap Stock Issued1
StockIssued1
328939
CY2021Q1 ctso Equity Contribution Proceeds In Transit
EquityContributionProceedsInTransit
0
CY2020Q1 ctso Equity Contribution Proceeds In Transit
EquityContributionProceedsInTransit
1798395
CY2021Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">1.    BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The interim consolidated financial statements of CytoSorbents Corporation (the “Company”) have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair statement of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2021. The results for the three months ended March 31, 2021 and 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2020, the Company's consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 24, 2020, the Company closed an underwritten public offering of 6,052,631 shares of its common stock at a public offering price of $9.50 per share (the “Offering”).  Gross proceeds from the Offering amounted to approximately $57.5 million and, after deducting the underwriting discounts and commissions and expenses related to the Offering, the Company received total net proceeds of approximately $53.8 million. See Note 3. As of March 31, 2021, the Company’s cash balance was approximately $68.5 million, which the Company expects will fund the Company’s operations well beyond the next twelve months. As a result, the Company has determined that the going concern risk has been substantially mitigated.</p>
CY2021Q1 us-gaap Cash
Cash
68500000
CY2021Q1 ctso Number Of Countries Where Flagship Product Is Marketed And Distributed
NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed
67
CY2021Q1 ctso Number Of Patents United States
NumberOfPatentsUnitedStates
16
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 ctso Foreign Currency Transaction Gain Loss Excluding Tax
ForeignCurrencyTransactionGainLossExcludingTax
-1306000
CY2020Q1 ctso Foreign Currency Transaction Gain Loss Excluding Tax
ForeignCurrencyTransactionGainLossExcludingTax
-668000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
65000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
47000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1622401
CY2020Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1164635
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1176067
CY2020Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1222062
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
309733
CY2020Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
287102
CY2021Q1 us-gaap Advertising Expense
AdvertisingExpense
154000
CY2020Q1 us-gaap Advertising Expense
AdvertisingExpense
31500
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. The valuation of options granted is a significant estimate in these consolidated financial statements.</p>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from government agencies in the United States. (See Note 4 for further information relating to the Company’s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2021, one distributor accounted for approximately 21% of outstanding grants and accounts receivable.  As of December 31, 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of outstanding grants and accounts receivables. For the three months ended March 31, 2021 one distributor accounted for approximately 11% of the Company's total revenue and for the three months ended March 31, 2020, no agency, distributor, or direct customer represented more than 10% of the Company’s total revenue. </p>
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q1 us-gaap Share Price
SharePrice
6.53
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27200000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
49000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
667000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
729000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5165204
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.36
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M3D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
65880
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.66
CY2021Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47832
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.25
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17031
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.13
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5166221
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.39
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0047
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0103
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.68
CY2021Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3677482
CY2021Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.26
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9179984
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1998117
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.12
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
65880
CY2021Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0916
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.82
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
45906
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.83
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
529352
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.11
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1488739
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.10
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5300000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10598847
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8707310
CY2021Q1 ctso Number Of Primary Revenue Streams
NumberOfPrimaryRevenueStreams
2
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2759368
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2996679
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
1313239
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
1014652
CY2021Q1 ctso Debt Instrument Non Refundable Fee Upon Termination Or Maturity Percent
DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent
0.025
CY2021Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
89000
CY2021Q1 ctso Executive Employment Agreements Initial Term
ExecutiveEmploymentAgreementsInitialTerm
P3Y
CY2021Q1 ctso License Period
LicensePeriod
P18Y
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
447485
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
461064
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581638
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
462896
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
923960
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1029123
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
923960
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1029123
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
462896
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
145153
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
82503
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
90386
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
99021
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
44001
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
923960
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
230865
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
234000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y

Files In Submission

Name View Source Status
0001104659-21-060974-index-headers.html Edgar Link pending
0001104659-21-060974-index.html Edgar Link pending
0001104659-21-060974.txt Edgar Link pending
0001104659-21-060974-xbrl.zip Edgar Link pending
ctso-20210331.xsd Edgar Link pending
ctso-20210331x10q.htm Edgar Link pending
ctso-20210331x10q_htm.xml Edgar Link completed
ctso-20210331xex31d1.htm Edgar Link pending
ctso-20210331xex31d2.htm Edgar Link pending
ctso-20210331xex32d1.htm Edgar Link pending
ctso-20210331xex32d2.htm Edgar Link pending
ctso-20210331_cal.xml Edgar Link unprocessable
ctso-20210331_def.xml Edgar Link unprocessable
ctso-20210331_lab.xml Edgar Link unprocessable
ctso-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending